Juventas

China
Goubangzi, Liaoning, China

Company profile

Juventas company profile

Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.

Business identity

Contact email
[email protected]
Phone number
010-65960098
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
4
Total equity funding
$101.6M
Last funding
Series C / $63.3M / 2021-07-12
Last equity funding
Series C / $63.3M
Investors
11
Lead investors
4
Founders
1
Articles
3

Founders and investors

Founders

Guang Ming Wang

Lead investors

CASI PharmaceuticalsCICCHaisong CapitalRedhill Capital

Investors

CASI PharmaceuticalsCICCDelian CapitalPanacea VentureTianjin Venture Capital